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Abstract The increased glucose consumption of many tumor 
cells depends to a large extent on the overexpression of 
hexokinase Type II. In a previous study we isolated and 
sequenced the hepatoma Type 1I hexokinase promoter and 
showed that it is activated by glucose in the highly glycolytic AS- 
30D hepatoma cell line under study, but not activated in control 
hepatocytes [Mathupala, S.P., Rempel, A. and Pedersen, P.L. 
(1995) J. Biol. Chem. 270, 16918-169251. Here we report that 
the promoter of the hexokinase Type H gene is maximally 
activated by glucose at concentrations above 5 mM. Moreover, 
the data strongly suggest that glucose can act alone without 
requirement for metabolism. Also, glucose-mediated promoter 
activation is markedly potentiated by cAMP. This response may 
serve as a strategy for cancer cells to maintain the hexokinase 
transcription rate high to ensure an efficient glucose utilization 
even under conditions where carbohydrates are limiting. 
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1. Introduction 
transfection assays in hepatoma cells but not in normal hepa- 
tocytes [4]. Elucidation of the glucose signaling pathway in 
tumor cells might help explain the molecular basis of hexoki- 
nase overexpression. 
In the present paper we first inquired whether glucose itself 
or a specific glycolytic intermediate is responsible for the glu- 
cose responsiveness of the tumor hexokinase Type II promo- 
ter. For these studies we used the highly glycolytic, rapidly 
growing rat hepatoma cell line AS-30D. This cell line has been 
characterized in this laboratory with respect o its high glyco- 
lytic rate and the role of hexokinase in this process [4,11]. 
Transient ransfection of hepatoma cells with the tumor hex- 
okinase Type II promoter fused to a luciferase reporter were 
used to determine the effect of glucose, glucose analogs, and 
other substrates on promoter activity. In a second set of stu- 
dies, we inquired whether an interaction exists between glu- 
cose and the cAMP/PKA (protein kinase A) signaling path- 
way. Our results from the two sets of studies suggest hat 
glucose can act alone on the hexokinase Type II promoter, 
and that the effect of glucose can be potentiated by activating 
the cAMP/PKA signal transduction pathway. 
The capacity to perform a high rate of glycolysis even under 
aerobic conditions is among the most characteristic biochem- 
ical phenotypes for animal and human cancers [1-3]. Hexoki- 
nase, the first enzyme of the glycolytic pathway, plays a pivo- 
tal role in glucose metabolism in transformed cells. Its 
activity, mRNA levels, and transcription rate, are strikingly 
increased in tumor cells relative to normal cells [4-7]. The 
hexokinase reaction which phosphorylates glucose is essential 
for further metabolism of glucose and provides the cell, not 
only with energy, but also with precursors for biosynthesis of 
lipids and nucleic acids. As high hexokinase levels are man- 
datory for the efficient utilization of glucose in many tumor 
cells, it is of interest o assess the effect of glucose itself on 
hexokinase gene expression. 
There are four hexokinase isozymes in mammalian tissues 
(HK I-IV). In most of the tumors studied to date it is hex- 
okinase Type II which is found to be markedly overexpressed 
in highly glycolytic tumors [4-6,8]. In adipose tissue it has 
been demonstrated that hexokinase Type II activity can be 
increased in response to glucose [9,10]. Further we have 
shown recently that a 4.3 kbp region of the proximal promo- 
ter of the tumor hexokinase Type II gene confers glucose 
responsiveness to a heterologous reporter gene in transient 
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2. Material and methods 
2.1. Materials 
RPMI 1640 tissue culture medium, glucose analogs, forskolin and 
IBMX were purchased from Sigma. pGL-2 luciferase vector and pSV- 
I]-galactosidase control vector were from Promega. H89 was pur- 
chased from Calbiochem. Chemiluminescence was measured using a 
TD-20e luminometer (Turner Designs/Promega). Electroporation was 
carried out in a Cell-Porator electroporator (Life Technologies, Inc.). 
AS-30D hepatoma cells were propagated, harvested, and purified as 
described [4]. 
2.2. Plasmids and electroporation 
Electroporation was carried out as described by Mathupala et al. 
[4]. Briefly 10 ~tg of the hexokinase promoter-luciferase construct and 
2.5 ktg of a SV40 promoter 13-galactosidase control vector were trans- 
fected in AS-30D cells by electroporation. The cells were incubated 
for 24 h either in basal medium (glucose-free RPMI 1640 supplemen- 
ted with 1 mM pyruvate) or in basal medium containing the various 
agents as indicated. For experiments in which enzyme inhibitors 
(mannoheptulose, glucosamine, or H89) were included the cells were 
first pretreated with the inhibitor for 2 h before challenging with the 
inducing agent. Cell extracts were assayed for luciferase and ~-galac- 
tosidase activity as we have previously described [4]. For each experi- 
ment the luciferase activity was normalized to the I~-galactosidase 
activity derived from the cotransfected control plasmid pSV-[~-galac- 
tosidase. 
2.3. Enzyme assays 
The activities of luciferase and [~-galactosidase were assayed essen- 
tially as described by the manufacturer using 20 ~tl and 100 gl cell 
extracts respectively. Hexokinase activity was determined spectropho- 
tometrically in a glucose 6-phosphate dehydrogenase coupled assay 
[12]. Hexokinase activity is expressed as milliunits (mU) defined as 
the formation of one nmol of NADPH per min. 
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3. Results and discussion 
We first investigated the effect of glucose concentration  
the tumor hexokinase Type II promoter in transient transfec- 
tion experiments using the promoter-luciferase-reporter con- 
struct. Glucose induced promoter activity in a concentration- 
dependent manner (Fig. 1). The sugar did not stimulate pro- 
moter activity significantly below concentrations of 5 mM as 
compared to control samples grown in media without glucose. 
Maximal activation was achieved at a glucose concentration 
of 25 mM resulting in a 2-3-fold increase in promoter activity. 
In order to address the question of whether glucose alone 
or a downstream glycolytic intermediate is responsible for 
activating the tumor hexokinase Type II promoter, experi- 
ments were first carried out with 5 different glucose analogs 
(Fig. 2). These included 3-0-methylglucose (3-OMetGlc), 
which cannot be phosphorylated, 2-deoxyglucose (2-DOG) 
which is phosphorylated by hexokinase to 2-DOG-6-P but 
not further metabolized, fructose, which can either be phos- 
phorylated by hexokinase or bypass the hexokinase step upon 
entering the glycolytic pathway, and galactose which bypasses 
the hexokinase step. The data show that only glucose and 
fructose markedly activate the tumor hexokinase Type II pro- 
moter. The simplest explanation of these results is that both 
glucose and fructose are activators of the promoter as no 
glycolytic intermediate, i.e. neither 2-DOG-6-P derived from 
2-DOG nor further downstream etabolites provided by ga- 
lactose, appreciably activates the promoter. Nevertheless, the 
experiment is not conclusive as 3-OMetGlc which is not phos- 
phorylated failed to activate the promoter and 2-DOG, be- 
cause of its toxicity to hepatoma cells at the high concentra- 
tions (25 mM) used for the other sugars, had to be used at a 
low concentration. [Toxicity of 2-DOG to cells at high con- 
centrations resulting in cell death has been observed by others 
[13] and is poorly understood.] 
For the above reasons, we examined also the action of 
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Fig. 1. Dose-dependent transcriptional activation of the tumor hexo- 
kinase Type II promotor by glucose. Glucose responsiveness of the 
tumor hexokinase Type II promotor was measured in transiently 
transfected AS-30D cells using the promoter-luciferase reporter con- 
struct. The cells were exposed to medium containing the indicated 
concentration f glucose. Luciferase activity in cell extracts was as- 
sayed 24 h posttransfection. Luciferase activity is expressed as rela- 
tive units. The activity at 0 mM glucose was arbitrarily set at 1. 
Data points represent the mean+ S.E.M. of at least 5 independent 
experiments. 
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Fig. 2. Effect of various sugars and glucose analogs on the tumor 
hexokinase Type II promotor activity. AS-30D hepatoma cells were 
transfected with the promoter-luciferase construct and grown either 
in basal medium or in basal medium with the additions as indi- 
cated. For each compound a concentration f 25 mM was used, ex- 
cept for 2-DOG which was added to a final concentration f 0.08 
mM. Luciferase activity was assayed 24 h posttransfection. Lucifer- 
ase activity in control samples incubated in basal medium was arbi- 
trarily set at 1. Each data point represents he mean + S.E.M. of at 
least 4 independent experiments. 
hexokinase inhibitors alone or in combination with glucose, 
on promoter activity. Should metabolites downstream from 
glucose in the glycolytic pathway be the activating signals, 
inhibition of hexokinase activity would be expected to prevent 
or at least diminish glucose-mediated promoter activation. We 
chose two different inhibitors of hexokinase, mannoheptulose 
and glucosamine. Fig. 3 illustrates the inhibitory potential of 
these two compounds on total hexokinase activity in AS-30D 
hepatoma cells. At a concentration of 20 mM, hexokinase 
activity was inhibited by 84% and 74% by mannoheptulose 
and glucosamine, respectively. When used in our transfection 
system, glucosamine exhibited no inhibitory effect while man- 
noheptulose imparted only a slight inhibitory effect on pro- 
moter activity (Fig. 4). However, in the presence of glucose 
the observed promoter activation (3.31 for mannoheptulose, 
2.2 for glucosamine) was not only higher than with the corre- 
sponding lucose concentration alone, but also higher than 
the maximal activation achieved by glucose alone (Fig. 1). 
The additional activation of glucosamine is hard to visualize 
in Fig. 4, but for this experiment a glucose concentration f
only 2.5 mM was used, which alone showed almost no effect 
on promoter activity (Fig. 1) compared to a 2.2-fold increase 
in the presence of glucosamine. This suggests that elevated 
intracellular glucose concentrations which accumulate due to 
the inhibition of hexokinase cause an increase in promoter 
activity. To further test this possibility, we used the glucose 
analog 2-DOG in combination with glucose. Due to the in- 
hibitory effect of 2-DOG-6-P on hexokinase activity, the si- 
multaneous addition of glucose and 2-DOG would be ex- 
pected to result in promoter activation. Consistent with this 
view, under these conditions 2-DOG was able to activate the 
promoter in a concentration-dependent ma ner (Fig. 4). Tak- 
en together these findings point to glucose itself as an activa- 
tor of the hexokinase Type II promoter. Although the failure 
of 3-OMetGlc to activate the promoter (see above) seems 
inconsistent with glucose being the stimulating agent, a low 
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uptake of this glucose analog, or the structural difference be- 
tween glucose and 3-O-methylglucose p r se, could have pre- 
vented this analog from activating the promoter. In addition 
to glucose, fructose might be another potent activator of the 
hexokinase Type II promoter, although additional experi- 
ments will be necessary to distinguish among fructose and 
intermediates thereof. 
lit should be noted that in the set of experiments described 
above, in contrast o those described earlier (Fig. 2), 2-DOG 
could be used at relatively high concentrations without toxi- 
city to the cells. This is most likely due to the presence of 
glucose in the above experiments.] 
Consistent with our finding that glucose promotes tran- 
scriptional regulation of hexokinase Type II in tumor cells, 
are data reported by Bernstein [14] investigating hexokinase 
Type II activity in fat pads using an in vitro assay. Glucose 
and fructose but not galactose showed the capacity to increase 
hexokinase II activity 1.5 to 2-fold. 2-DOG caused a decrease, 
and 3-OMetGlc a slight increase. However, based on the ob- 
servation that glucose 6-phosphate itself is an inducer of hex- 
okinase activity, Bernstein concluded that glucose 6-phos- 
phate mediates the glucose effect on hexokinase activity. 
This would be paradoxical because high intracellular glucose 
6-phosphate concentrations favor down regulation of glucose 
phosphorylation. The known inhibition of hexokinase activity 
by glucose 6-phosphate [9] is consistent with this concept. 
Induction of hexokinase xpression by glucose and fructose, 
the two main carbohydrates in the blood stream, seems to be 
more physiological. Nevertheless, our studies do not exclude 
the possibility that, in addition to glucose, glycolytic or post- 
glycolytic intermediates might function as regulators of the 
tumor hexokinase Type II promoter. 
Following the above set of studies, we turned our attention 
to a study of the effects of cAMP and cAMP plus glucose on 
the activity of the tumor hexokinase Type II promoter. Pre- 
viously we reported the activation of the tumor hexokinase 
Type II promoter by dibutyryl cAMP (dbtcAMP) [4], a mem- 
brane-permeable cAMP analog. In order to further evaluate 
the specificity of promoter activation by this cAMP analog 
and the possible involvement of the PKA signal transduction 
100 
80 
60 
40 
20 
4 8 12 16 20 
Inhib i tor  [raM] 
Fig. 3. Inhibition of tumor hexokinase activity by mannoheptulose 
(• )  and glucosamine ( ). Aliquots of AS-30D hepatoma cell homo- 
genates were incubated 10 min at 25°C with the indicated concen- 
tration of inhibitor. Hexokinase activity was assayed as described in 
section 2. 
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Fig. 4. Effect of hexokinase inhibitors on the glucose reponsiveness 
of the tumor hexokinase Type II promoter. AS-30D hepatoma cells 
were transfected with the promotor-luciferase construct and prior 
incubated for 2 h in basal medium containing the compounds as in- 
dicated. The cells were then incubated for 24 h with or without he 
addition of glucose. Luciferase activity was assayed in cell extracts 
and the activity in control samples incubated in basal medium alone 
was arbitrarily set at 1. (Concentrations used, from left to right: 
0/25 mM glucose [Control], 12.5 mM mannoheptulose/12.5 mM glu- 
cose, 7.5 mM glucoseamine/2.5 mM glucose, 5 or 7.5 mM 2-DOG/ 
20 or 17.5 mM glucose). Data points represent the mean+S.E.M. 
of at least 4 separate experiments. 
pathway in promoter egulation, we tested the effect of for- 
skolin, an activator of adenylyl cyclase, and IBMX, an inhi- 
bitor of cyclic nucleotide phosphodiesterases. A  shown in 
Fig. 5, incubation with either forskolin or IBMX resulted in 
a 2 and 1.5-fold activation, respectively, of the tumor hexoki- 
nase Type II promoter, which is in the same range as the 
stimulation observed with dibutyryl cAMP. Thus, cAMP gen- 
erated either exogenously or endogenously increases promoter 
activity. To seek additional evidence that PKA mediates ti- 
mulation of promoter activity, we used H89, a selective and 
potent inhibitor of PKA [15]. Used alone, H89 caused a slight 
but consistent decrease in promoter activity. Because protein 
kinases exhibit a low basal activity in the absence of added 
cyclic nucleotides [16], this indicates that the PKA pathway 
contributes to the 'basal activity' of the hexokinase Type II 
promoter. However, H89 was not able to completely prevent 
the dbtcAMP-mediated activation, although it was less than 
with dbtcAMP alone. It might be that even at the concentra- 
tions used, H89 was not sufficiently potent to completely an- 
tagonize the activation of PKA, or that there might be a way, 
other than stimulating PKA, by which cAMP mediates its 
effect on the tumor hexokinase Type II promoter. 
To obtain more insight into the glucose signaling pathway 
in AS-30D hepatoma cells, and as a first attempt o obtain 
information about its possible cross-talk with other signaling 
pathways, we investigated interaction of this sugar with the 
PKA pathway. AS-30D hepatoma cells were transfected with 
the promoter-reporter construct and exposed for 24 h either 
to glucose and dbtcAMP alone or simultaneously. As shown 
in Fig. 6, the increase in promoter activity (,-, 6-fold) exhib- 
ited by the combined treatment of glucose and dbtcAMP was 
always more than the addition of promoter activation of both 
agents eparately (,--2-fold, each). Synergistic interactions be- 
tween various signal transduction pathways are commonly 
involved in gene regulation providing multiple sites of regula- 
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tion. Protein phosphorylation by cAMP-dependent protein 
kinase represents the central mechanism in the signal trans- 
duction of glucagon, the hormone which is present at high 
concentrations when blood glucose levels are low (fasting 
state). The synergism of glucose and cAMP might be a strat- 
egy of the cancer cell to maintain hexokinase l vels high even 
under conditions when glucose concentrations are low. This 
strategy might facilitate glucose consumption when carbohy- 
drates are limited. More importantly, when facing a high glu- 
cose availability, again the cancer cell can utilize the available 
glucose efficiently without a lag period. Glucokinase which is 
the predominant hexokinase isozyme in normal hepatocytes is 
up-regulated by glucose [9]. However, cAMP decreases gluco- 
kinase expression [17]. Therefore, the synergistic activation of 
the tumor hexokinase Type II promoter by cAMP and glucose 
clearly provides the cancer cell with a growth advantage over 
normal cells. 
Further downstream events in the glucose signaling path- 
way still remain an open question. A synergistic effect of 
glucose and cAMP has been reported for the insulin secretion 
of 13-cells [18]. In the insulinoma cell line INS-l, glucose acti- 
vates MAP kinase. This activation is synergistically enhanced 
by increased levels of cAMP [19]. This raises the possibility 
that glucose might mediate its effect on tumor hexokinase 
Type II promoter activity in AS-30D hepatoma cells by a 
similar mechanism. However, the identification of the proxi- 
mate glucose signal requires further investigations. 
Glucose has been implicated to play a crucial role in reg- 
ulating gene expression for a variety of enzymes attesting to 
its importance in regulating energy metabolism. For example, 
the transcriptional rates of L-type pyruvate kinase and lipo- 
genic enzymes are increased in response to glucose [20-23]. In 
cases tudied thus far a glycolytic intermediate, most probably 
glucose 6-phosphate, has been suggested to mediate the glu- 
cose response. The activation of the tumor hexokinase Type II 
promoter by glucose itself seems to be unique. Significantly, in 
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Fig. 5. Effect of exogenous and endogenous generated cAMP on the 
tumor hexokinase Type II promotor activity. AS-30D hepatoma 
cells were transfected with the promoter-luciferase construct and ex- 
posed to media containing dbtcAMP (100 IxM), forskolin (20 p.M), 
IBMX (150 p_M) or H89 (30 /.tM). In experiments in which H89 
and dbtcAMP were used together, the latter was added after a 2 h 
prior incubation period of cells with H89 alone. Luciferase activity 
in cell extracts was determined after 24 h. The luciferase activity in 
control samples grown in basal medium was arbitrarily set at 1. 
Data points represent mean + S.E.M. of at least 4 different experi- 
ments. 
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Fig. 6. Synergistic effect of glucose and cAMP on the tumor hexoki- 
nase Type II promotor activity, AS-30D cells transfected with the 
promotor-luciferase construct were exposed to glucose (25 raM), 
dbtcAMP (100 BM) or a combination thereof. Luciferase activity 
was determined 24 h posttransfection. The activity in control sam- 
ples grown in basal medium was arbitrarily set at 1. Data points re- 
present he mean + S.E.M. of at least 6 independent experiments. 
rapidly growing tumor cells, where hexokinase l vels are many 
fold higher than in normal cells, and are required for the high 
glucose catabolic phenotype, one can hypothesize that hexo- 
kinase Type II may play a major role in determining the 
glucose responsiveness. Along these lines, it is important o 
note that we have previously shown that the tumor Type II 
hexokinase promoter is activated by glucose in transfected 
hepatoma cells (AS-30D) which express the high glycolytic 
phenotype, but not in control hepatocytes [4]. Thus data pre- 
sented here strengthen the view that hexokinase is pivotal for 
tumor metabolism. 
In summary, we have shown that glucose alone is an acti- 
vator of the tumor hexokinase Type II promoter and that this 
activation can be potentiated by cAMP. This response is likely 
an adaptive response to allow tumor cells to better utilize 
glucose and hence provide them with a growth advantage 
over normal cells. 
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